These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 19192640)

  • 21. [Second-line treatment and targeted therapy of advanced lung cancer].
    Nakamura Y; Yamamoto N
    Gan To Kagaku Ryoho; 2009 May; 36(5):710-6. PubMed ID: 19461168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer.
    Di Maio M; Chiodini P; Georgoulias V; Hatzidaki D; Takeda K; Wachters FM; Gebbia V; Smit EF; Morabito A; Gallo C; Perrone F; Gridelli C
    J Clin Oncol; 2009 Apr; 27(11):1836-43. PubMed ID: 19273711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
    Jotte R; Conkling P; Reynolds C; Galsky MD; Klein L; Fitzgibbons JF; McNally R; Renschler MF; Oliver JW
    J Clin Oncol; 2011 Jan; 29(3):287-93. PubMed ID: 21135284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Analysis of adverse events of amrubicin hydrochloride for pretreated lung cancer patients].
    Takase M; Maruoka H; Maeda R; Shibata K
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1789-92. PubMed ID: 18030011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial.
    Sawa T; Yana T; Takada M; Sugiura T; Kudoh S; Kamei T; Isobe T; Yamamoto H; Yokota S; Katakami N; Tohda Y; Kawakami A; Nakanishi Y; Ariyoshi Y
    Invest New Drugs; 2006 Mar; 24(2):151-8. PubMed ID: 16502350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.
    Inoue A; Kobayashi K; Usui K; Maemondo M; Okinaga S; Mikami I; Ando M; Yamazaki K; Saijo Y; Gemma A; Miyazawa H; Tanaka T; Ikebuchi K; Nukiwa T; Morita S; Hagiwara K;
    J Clin Oncol; 2009 Mar; 27(9):1394-400. PubMed ID: 19224850
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival among patients with platinum resistant, locally advanced non-small cell lung cancer treated with platinum-based systemic therapy.
    d'Amato TA; Pettiford BL; Schuchert MJ; Parker R; Ricketts WA; Luketich JD; Landreneau RJ
    Ann Surg Oncol; 2009 Oct; 16(10):2848-55. PubMed ID: 19609620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [S-1 activity in non-small cell lung cancer in clinical practice].
    Inagaki M; Onuki T; Iguchi K; Ogata T; Hayashi Y; Saito K; Wakai Y; Takabe K; Shinohara Y; Suzuki K; Ohtani T; Horikoshi K
    Gan To Kagaku Ryoho; 2009 May; 36(5):763-7. PubMed ID: 19461174
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of patients with stage III nonsmall cell lung cancer treated with chemotherapy and radiation with and without surgery.
    Caglar HB; Baldini EH; Othus M; Rabin MS; Bueno R; Sugarbaker DJ; Mentzer SJ; Jänne PA; Johnson BE; Allen AM
    Cancer; 2009 Sep; 115(18):4156-66. PubMed ID: 19551884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.
    Hirose T; Sugiyama T; Kusumoto S; Shirai T; Nakashima M; Yamaoka T; Okuda K; Ogura K; Ohnishi T; Ohmori T; Adachi M
    Anticancer Res; 2009 May; 29(5):1733-8. PubMed ID: 19443395
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach.
    Grossi F; Aita M; Defferrari C; Rosetti F; Brianti A; Fasola G; Vinante O; Pronzato P; Pappagallo G
    Oncologist; 2009 May; 14(5):497-510. PubMed ID: 19423674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, open-label, phase III trial comparing amrubicin versus docetaxel in patients with previously treated non-small-cell lung cancer.
    Yoshioka H; Katakami N; Okamoto H; Iwamoto Y; Seto T; Takahashi T; Sunaga N; Kudoh S; Chikamori K; Harada M; Tanaka H; Saito H; Saka H; Takeda K; Nogami N; Masuda N; Harada T; Kitagawa H; Horio H; Yamanaka T; Fukuoka M; Yamamoto N; Nakagawa K
    Ann Oncol; 2017 Feb; 28(2):285-291. PubMed ID: 28426104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Two cases of severe myelosuppression from amrubicin in previously-treated small cell lung cancer].
    Suzuki H; Sasada S; Matsuda Y; Otani Y; Morishita N; Kobayashi M; Okamoto N; Hirashima T; Matsui K; Kawase I
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):491-3. PubMed ID: 18347402
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study.
    Takeda K; Takifuji N; Negoro S; Furuse K; Nakamura S; Takada Y; Hoso T; Hayasaka S; Nakano T; Araki J; Senba H; Iwami F; Yamaji Y; Fukuoka M; Ikegami H
    Invest New Drugs; 2007 Aug; 25(4):377-83. PubMed ID: 17351748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.
    Luciani A; Bertuzzi C; Ascione G; Di Gennaro E; Bozzoni S; Zonato S; Ferrari D; Foa P
    Lung Cancer; 2009 Oct; 66(1):94-6. PubMed ID: 19171407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gender difference in treatment outcomes in patients with stage III non-small cell lung cancer receiving concurrent chemoradiotherapy.
    Sekine I; Sumi M; Ito Y; Tanai C; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Tamura T
    Jpn J Clin Oncol; 2009 Nov; 39(11):707-12. PubMed ID: 19692418
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
    Wu C; Jiang J; Shi L; Xu N
    Anticancer Res; 2008; 28(6B):3997-4002. PubMed ID: 19192663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gender difference in hematological toxicity among lung cancer patients receiving amrubicin monotherapy.
    Makihara RA; Makino Y; Yamamoto N; Yokote N; Nokihara H; Sekine I; Ohe Y; Tamura T; Yamamoto H
    Jpn J Clin Oncol; 2012 Dec; 42(12):1187-91. PubMed ID: 23081985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Amrubicin in Non-Small-Cell Lung Cancer Patients Beyond Third-Line Therapy.
    Saigusa M; Asada K; Akamatsu T; Tanaka Y; Endo Y; Yamamoto A; Morita S; Shirai T
    Oncol Res Treat; 2019; 42(1-2):52-56. PubMed ID: 30537755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer.
    Ono A; Naito T; Murakami H; Takahashi T; Nakamura Y; Tsuya A; Kaira K; Igawa S; Shukuya T; Tamiya A; Kaira R; Endo M; Yamamoto N
    Int J Clin Oncol; 2010 Apr; 15(2):161-5. PubMed ID: 20198400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.